$Eli Lilly and Co (LLY.US)$ [Share Link: Eli Lilly revises 2...
US pharmaceutical giant Eli Lilly has revised its sales and profit forecasts for 2024 upward.
Overall sales fell short of analysts' expectations in January-March (first quarter), but sales of the obesity treatment drug “Zepbound” greatly exceeded expectations.
Overall sales fell short of analysts' expectations in January-March (first quarter), but sales of the obesity treatment drug “Zepbound” greatly exceeded expectations.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
